# Phase 1/2 Squamous Cell Carcinoma of: 63 recruiting (2026)

ClinicalTrials.gov lists 63 trials in phase 1/2 for Squamous Cell Carcinoma of Head and Neck that are recruiting or not yet recruiting.

## The full list

Recruiting Phase 1/2 Squamous Cell Carcinoma of Head and Neck trials: 63 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/squamous-cell-carcinoma-of-head-and-neck

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 63
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941362 | 177Lu-ACT319 in FAP Expressing Solid Tumors | Actithera INC. | Phase 1/2 | Not yet recruiting | FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC) | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941362) |
| November 5, 2026 | NCT07920289 | Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients | Assuta Ashdod Hospital | Phase 1/2 | Not yet recruiting | Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920289) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| July 28, 2026 | NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730021) |
| June 25, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667400) |
| June 23, 2026 | NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer | Glycyx Therapeutics | Phase 1/2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662720) |
| June 1, 2026 | NCT07617805 | EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC | Beijing Biotech | Phase 1/2 | Recruiting | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617805) |
| May 22, 2026 | NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | InduPro, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma... | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602842) |
| April 27, 2026 | NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | Washington University School of Medicine | Phase 1/2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552558) |
| February 23, 2026 | NCT07428148 | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma | NYU Langone Health | Phase 1/2 | Not yet recruiting | Oropharyngeal Squamous Cell Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428148) |
| January 14, 2026 | NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors | Onchilles Pharma Inc | Phase 1/2 | Recruiting | Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck... | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339176) |
| October 9, 2025 | NCT07213934 | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell... | University of Cincinnati | Phase 1/2 | Recruiting | Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213934) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 15, 2025 | NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | GI Innovation, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic... | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172802) |
| September 2, 2025 | NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | One-carbon Therapeutics AB | Phase 1/2 | Recruiting | Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07151040) |
| August 22, 2025 | NCT07136545 | A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck... | Taipei Veterans General Hospital, Taiwan | Phase 1/2 | Recruiting | HNSCC | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136545) |
| August 11, 2025 | NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | AstraZeneca | Phase 1/2 | Recruiting | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115043) |
| August 7, 2025 | NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Terremoto Biosciences Inc. | Phase 1/2 | Recruiting | Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109726) |
| August 6, 2025 | NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | Fudan University | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105592) |
| July 10, 2025 | NCT07059221 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059221) |
| June 25, 2025 | NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | West China Hospital | Phase 1/2 | Recruiting | DCSZ11, Solid Tumors, HNSCC | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035249) |
| June 22, 2025 | NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Tasca Therapeutics | Phase 1/2 | Recruiting | Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07030257) |
| May 29, 2025 | NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors, Advanced Breast Cancer | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993844) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 2 |
| DualityBio Inc. | 2 |
| Onchilles Pharma Inc | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Volastra Therapeutics, Inc. | 1 |
| One-carbon Therapeutics AB | 1 |
| GI Innovation, Inc. | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Doma Biopharmaceutical（Suzhou）Co., Ltd. | 1 |
| Nykode Therapeutics ASA | 1 |
| Neonc Technologies, Inc. | 1 |
| CJ Bioscience, Inc. | 1 |
| Washington University School of Medicine | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| InduPro, Inc. | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| Inhibrx Biosciences, Inc | 1 |
| University of Cincinnati | 1 |
| Medsyn Biopharma, LLC | 1 |
| University Medical Center Groningen | 1 |
| Glycyx Therapeutics | 1 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 1 |
| [Yuhan Corporation](https://specstream.ai/data/clinical-trials/company/yuhan-corporation) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 40 |
| Spain | 11 |
| South Korea | 10 |
| China | 10 |
| Australia | 9 |
| Japan | 8 |
| France | 8 |
| Taiwan | 8 |
| United Kingdom | 7 |
| Germany | 6 |
| Italy | 5 |
| Belgium | 4 |
| Netherlands | 4 |
| Poland | 3 |
| Singapore | 3 |
| Canada | 3 |
| Ireland | 3 |
| Puerto Rico | 2 |
| Portugal | 2 |
| Hungary | 1 |
| Norway | 1 |
| Malaysia | 1 |
| Moldova | 1 |
| Hong Kong | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
